Bupivacaine - Liquidia Technologies

Drug Profile

Bupivacaine - Liquidia Technologies

Alternative Names: LIQ865; LIQ865A; LIQ865A bupivacaine formulation; LIQ865B; LIQ865B bupivacaine formulation

Latest Information Update: 06 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Liquidia Technologies
  • Class Analgesics; Anilides; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Postoperative pain

Most Recent Events

  • 24 May 2017 Initial efficacy and safety data from a phase I trial in Post-operative pain (In volunteers) released by Liquidia Technologies
  • 24 May 2017 Liquidia Technologies completes a phase I trial in Post-operative pain (In volunteers) in Denmark
  • 01 Feb 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top